肝动脉灌注化疗治疗晚期肝细胞癌:预测生存的影像与临床因素
单中心回顾性研究纳入180例接受5-FU联合顺铂方案HAIC的晚期肝细胞癌患者,中位总生存期7.6个月,客观缓解率15%。多因素分析显示浸润性肿瘤生长和环状动脉强化是生存期缩短的预处理影像因素,早期无治疗反应和较高Child-Pugh分级为强预后不良因素,而≥3个HAIC周期和高剂量HAIC有利于生存。
要点
- 预处理影像见浸润性生长或环状动脉强化提示HAIC预后较差。
- 早期影像无治疗反应和较高Child-Pugh分级是强预后不良因素。
- ≥3个HAIC周期和高剂量HAIC与生存期延长相关。
关键影像表现/征象
- 预处理影像中浸润性肿瘤生长与总生存期缩短相关(HR 1.002,p=.03)。
- 预处理影像中环状动脉强化与总生存期缩短相关(HR 3.040,p<.001)。
诊断标准与关键数值
- 中位总生存期为7.6个月(95%CI 6.1-9.1),客观缓解率为15%。
- 早期无治疗反应与不良预后相关(HR 2.064-6.491)。
- 较高Child-Pugh分级与不良预后相关(HR 2.010-2.815)。
- 接受≥3个HAIC周期与总生存期延长相关(HR 0.371,p=.001)。
- 高剂量HAIC与总生存期延长相关(HR 0.447,p<.001)。
临床应用与阅片要点
- 阅片时注意评估肿瘤生长方式(浸润性 vs 非浸润性)和动脉强化模式(环状 vs 非环状),辅助预后分层。
- 治疗后早期影像评估有无缓解,无缓解者提示预后不良。
- 结合Child-Pugh分级等临床肝功能指标综合判断HAIC获益可能性。
局限性
- 单中心回顾性研究设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE. The goal of this study was to evaluate radiologic and clinical factors associated with overall survival of advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy (HAIC). MATERIALS AND METHODS. This single-center retrospective study included 180 patients with advanced hepatocellular carcinoma who underwent HAIC with a 5-fluorouracil (250-500 mg/m2 for 5 hours) plus cisplatin (10-20 mg/m2 for 1-2 hours) regimen via an implantable port system. Survival curves were generated by the Kaplan-Meier method and compared by log-rank tests. Factors associated with overall survival were evaluated with Cox proportional hazard models. RESULTS. The median overall survival time was 7.6 months (95% CI, 6.1-9.1), and the objective response rate was 15%. In multivariate analysis, infiltrative tumor growth (hazard ratio [HR], 1.002; p = .03) and rimlike arterial enhancement (HR, 3.040; p < .001) were pretreatment radiologic factors associated with reduced overall survival. No early response to treatment (HR, 2.064-6.491) and higher Child-Pugh class (HR, 2.010-2.815) were strong prognostic factors of poor outcome. Treatment with three or more HAIC cycles (HR, 0.371; p = .001) and high-dose HAIC (HR, 0.447; p < .001) were favorable for increased overall survival. CONCLUSION. Infiltrative tumor growth and rimlike arterial enhancement in pre-treatment imaging studies were associated with poor prognosis, and better early radiologic response and preserved liver function reserve were strong indicators of prolonged survival. Recognizing these radiologic and clinical predictors may help optimize care of patients with hepatocellular carcinoma.
引用
- Kim B, Won JH, Kim J, et al. Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma: Radiologic and Clinical Factors Predictive of Survival. AJR Am J Roentgenol. 2021. PMID: 33852336. doi:10.2214/AJR.20.23213
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。